Skip to main content
SpringerLink
Log in

Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results

  • Educational Series
  • Current Technology in Cancer Research and Treatment
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the most frequently occurring primary tumour of the liver in adults and the third most common cause of cancer-related deaths in the world. The incidence of HCC is increasing both in Europe and in the United States due to the increasing prevalence of hepatitis C. Of recognised importance, when making decisions regarding the most appropriate management of a patient with HCC, is the involvement of a multidisciplinary team of hepatologists, hepatobiliary surgeons, a liver transplant team, interventional radiologists, and medical and radiation oncologists. This manuscript reviews the role of stereotactic body radiotherapy in HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States [see comment]. N Engl J Med 340:745–750

    Article  PubMed  CAS  Google Scholar 

  3. Bruix J, Sherman M (2005) Practice guidelines committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. AASLD Practice Guideline. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  4. American Joint Committee on Cancer (2002) Cancer staging handbook. Springer Verlag, New York

    Google Scholar 

  5. Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928

    Article  PubMed  CAS  Google Scholar 

  6. Pugh RN, Murray-Lyon IM, Dawson JL et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649

    Article  PubMed  CAS  Google Scholar 

  7. Christensen E (2004) Prognostic models including the Child-Pugh, MELD and Mayo risk scores — where are we and where should we go? J Hepatol 41:344–350

    Article  PubMed  Google Scholar 

  8. Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease [see comment]. Hepatology 33:464–470

    Article  PubMed  CAS  Google Scholar 

  9. Bruix J, Boix L, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer Cell 5:215–219

    Article  PubMed  CAS  Google Scholar 

  10. (1998) A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (clip) investigators [see comment]. Hepatology 28:751–755

  11. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  12. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comment]. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  13. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation [see comment]. Hepatology 30:1434–1440

    Article  PubMed  CAS  Google Scholar 

  14. Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224–1229

    Article  PubMed  CAS  Google Scholar 

  15. Vilana R, Bruix J, Bru C et al (1992) Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16:353–357

    Article  PubMed  CAS  Google Scholar 

  16. Liu L-X, Jiang H-C, Piao D-X (2002) Radiofrequence ablation of liver cancers. World J Gastroenterol 8:393–399

    PubMed  Google Scholar 

  17. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

    Article  PubMed  CAS  Google Scholar 

  18. Salem R, Hunter RD (2006) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys 66:S83–88

    PubMed  CAS  Google Scholar 

  19. Llovet J, Ricci S, Mazzaferro V, SHARP Investigators Study Group (2007) Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized placebo-controlled trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 25:LBA1

  20. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma [see comment]. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  21. Abrams RA, Pajak TF, Haulk TL et al (1998) Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 4:178–184

    PubMed  CAS  Google Scholar 

  22. Stillwagon GB, Order SE, Guse C et al (1989) 194 Hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a radiation therapy oncology group study. Int J Radiat Oncol Biol Phys 17:1223–1229

    PubMed  CAS  Google Scholar 

  23. Robertson JM, Lawrence TS, Dworzanin LM et al (1993) Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 11:1286–1293

    PubMed  CAS  Google Scholar 

  24. Dawson LA, McGinn CJ, Normolle D et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18:2210–2218

    PubMed  CAS  Google Scholar 

  25. Liu M-T, Li S-H, Chu T-C et al (2004) Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 34:532–539

    Article  PubMed  Google Scholar 

  26. Seong J, Park HC, Han KH, Chon CY (2003) Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys. 55:329–336

    PubMed  Google Scholar 

  27. Mornex F, Girard N, Beziat C et al (2006) Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma noneligible for curative therapies — mature results of the French phase Phase II RTF-1 Trial. Int J Radiat Oncol Biol Phys 66:1152–1158

    PubMed  Google Scholar 

  28. Park HC, Seong J, Han KH et al (2002) Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54:150–155

    Article  PubMed  Google Scholar 

  29. Kim DY, Park W, Lim DH et al (2005) Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 103:2419–2426

    Article  PubMed  Google Scholar 

  30. Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model [see comment] [Erratum appears in Int J Radiat Oncol Biol Phys 2002;53:1422]. Int J Radiat Oncol Biol Phys 53:810–821

    PubMed  Google Scholar 

  31. Lawrence TS, Ten Haken RK, Kessler ML et al (1992) The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 23:781–788

    PubMed  CAS  Google Scholar 

  32. Russell AH, Clyde C, Wasserman TH et al (1993) Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: Results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 27:117–123

    PubMed  CAS  Google Scholar 

  33. Lyman JT (1985) Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8:S13–19

    Article  PubMed  CAS  Google Scholar 

  34. Cheng JC-H, Wu JK, Huang CM et al (2002) Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 63:41–45

    Article  PubMed  Google Scholar 

  35. Cheng JC-H, Wu J-K, Lee PC-T et al (2004) Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60:1502–1509

    Article  PubMed  Google Scholar 

  36. Xu Z-Y, Liang S-X, Zhu J et al (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma [see comment]. Int J Radiat Oncol Biol Phys 65:189–195

    PubMed  Google Scholar 

  37. Blomgren H, Lax I, Goranson H et al (1998) Radiosurgery for tumors of in the body: clinical experience using a new method. J Radiosurg 1:63–74

    Article  Google Scholar 

  38. Blomgren H, Lax I, Naslund I, Svanstrom R (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34:861–870

    Article  PubMed  CAS  Google Scholar 

  39. Lax I, Blomgren H, Naslund I, Svanstrom R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:677–683

    Article  PubMed  CAS  Google Scholar 

  40. Kelsey CR, Shchefter R, Nash P et al (2003) Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for extracranial stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 57:S283

    Google Scholar 

  41. Cao M, Cardenes H, Langer M et al (2008) Evaluation of automatic volume match function for kilovoltage cone-beam CT (CBCT) guided patient setup. American Association of Physicists in Medicine, Houston, TX

    Google Scholar 

  42. Dawson LA, Eccles C, Bissonnette J-P, Brock KK (2005) Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 62:1247–1252

    PubMed  Google Scholar 

  43. Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170

    PubMed  CAS  Google Scholar 

  44. Wulf J, Guckenberger M, Haedinger U et al (2006) Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45:838–847

    Article  PubMed  Google Scholar 

  45. Choi BO, Jang HS, Kang KM et al (2006) Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 36:154–158

    Article  PubMed  Google Scholar 

  46. Méndez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol 45:831–837

    Article  PubMed  Google Scholar 

  47. Tse RV, Hawkins M, Lockwood G et al (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657–664

    Article  PubMed  Google Scholar 

  48. Cardenes H, Price T, Perkins S et al (2008) Phase I trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 72:S128–S129

    Google Scholar 

  49. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006

  50. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  51. Douglas BG, Fowler JF (1976) The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat Res 66:401–426

    Article  PubMed  CAS  Google Scholar 

  52. Park C, Papiez L, Zhang S et al (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy [see comment]. Int J Radiat Oncol Biol Phys 70:847–852

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Dr (RT041), Indianapolis, IN, 46202, USA

    Higinia R. Cárdenes

Authors
  1. Higinia R. Cárdenes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Higinia R. Cárdenes.

Additional information

Supported by an unrestricted educational grant from Merck Serono

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cárdenes, H.R. Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 11, 276–283 (2009). https://doi.org/10.1007/s12094-009-0355-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0355-5

Keywords

Search

Navigation